Walleye Trading
SABSW icon

Walleye Trading’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Walleye Trading’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,436
Closed -$268 – 4770
2025
Q3 		$268 Sell
11,436
-20,427
-64% -$682 ﹤0.01% 4303
2025
Q2 		$1.06K Hold
31,863
– – ﹤0.01% 4148
2025
Q1 		$828 Sell
31,863
-6,900
-18% -$386 ﹤0.01% 3951
2024
Q4 		$2.92K Buy
38,763
+23,258
+150% +$1.4K ﹤0.01% 4107
2024
Q3 		$558 Hold
15,505
– – ﹤0.01% 4008
2024
Q2 		$735 Hold
15,505
– – ﹤0.01% 4148
2024
Q1 		$605 Hold
15,505
– – ﹤0.01% 4636
2023
Q4 		$468 Hold
15,505
– – ﹤0.01% 4967
2023
Q3 		$1.08K Hold
15,505
– – ﹤0.01% 4857
2023
Q2 		$1.62K Hold
15,505
– – ﹤0.01% 4532
2023
Q1 		$558 Hold
15,505
– – ﹤0.01% 4745
2022
Q4 		$729 Hold
15,505
– – ﹤0.01% 4834
2022
Q3 		$1K Hold
15,505
– – ﹤0.01% 4883
2022
Q2 		$2K Hold
15,505
– – ﹤0.01% 4939
2022
Q1 		$7K Hold
15,505
– – ﹤0.01% 5042
2021
Q4 		$28K Sell
15,505
-14,495
-48% -$26.6K ﹤0.01% 4837
2021
Q3 		$28K Hold
30,000
– – ﹤0.01% 4789
2021
Q2 		$28K Buy
+30,000
New +$21.8K ﹤0.01% 4766

Other funds holding SABSW

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Trading's SABSW Position: Q4 2025 in Review

Walleye Trading sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2025, closing a stake of 11,436 shares — an estimated $268 sold.

Walleye Trading first reported a position in SABSW in Q2 2021 and held it in 18 quarters. The position peaked at $28K in Q4 2021. 7 funds tracked by Wall St. Rank hold SABSW as of Q4 2025.

  • Walleye Trading reported no remaining SAB Biotherapeutics Warrant position as of Q4 2025 after selling out during the quarter.
  • Walleye Trading sold 11,436 SAB Biotherapeutics Warrant shares in Q4 2025, an estimated $268.
  • Walleye Trading first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 18 quarters.
  • Walleye Trading's SAB Biotherapeutics Warrant position peaked at $28K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2025.

Based on Walleye Trading's 13F filing for Q4 2025, filed 13 Feb 2026.